175 related articles for article (PubMed ID: 34435356)
1. Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial.
Fjordén K; Ekberg S; Kuric N; Smedby KE; Lagerlöf I; Larsen TS; Jørgensen JM; de Nully Brown P; Jerkeman M
Br J Haematol; 2022 Jan; 196(2):437-440. PubMed ID: 34435356
[No Abstract] [Full Text] [Related]
2. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
3. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Brown JR; Byrd JC; Coutre SE; Benson DM; Flinn IW; Wagner-Johnston ND; Spurgeon SE; Kahl BS; Bello C; Webb HK; Johnson DM; Peterman S; Li D; Jahn TM; Lannutti BJ; Ulrich RG; Yu AS; Miller LL; Furman RR
Blood; 2014 May; 123(22):3390-7. PubMed ID: 24615777
[TBL] [Abstract][Full Text] [Related]
4. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.
Flinn IW; Kahl BS; Leonard JP; Furman RR; Brown JR; Byrd JC; Wagner-Johnston ND; Coutre SE; Benson DM; Peterman S; Cho Y; Webb HK; Johnson DM; Yu AS; Ulrich RG; Godfrey WR; Miller LL; Spurgeon SE
Blood; 2014 May; 123(22):3406-13. PubMed ID: 24615776
[TBL] [Abstract][Full Text] [Related]
5. Idelalisib in the management of lymphoma.
Cheah CY; Fowler NH
Blood; 2016 Jul; 128(3):331-6. PubMed ID: 27252232
[TBL] [Abstract][Full Text] [Related]
6. Idelalisib for the treatment of non-Hodgkin lymphoma.
Graf SA; Gopal AK
Expert Opin Pharmacother; 2016; 17(2):265-74. PubMed ID: 26818003
[TBL] [Abstract][Full Text] [Related]
7. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
8. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
Carpio C; Bouabdallah R; Ysebaert L; Sancho JM; Salles G; Cordoba R; Pinto A; Gharibo M; Rasco D; Panizo C; Lopez-Martin JA; Santoro A; Salar A; Damian S; Martin A; Verhoef G; Van den Neste E; Wang M; Couto S; Carrancio S; Weng A; Wang X; Schmitz F; Wei X; Hege K; Trotter MWB; Risueño A; Buchholz TJ; Hagner PR; Gandhi AK; Pourdehnad M; Ribrag V
Blood; 2020 Mar; 135(13):996-1007. PubMed ID: 31977002
[TBL] [Abstract][Full Text] [Related]
9. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
Burger JA; Okkenhaug K
Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
[TBL] [Abstract][Full Text] [Related]
10. Acute polyradiculopathy secondary to idelalisib in Relapsed Classical Hodgkin's lymphoma.
Barbieux S; Boyle EM; Baillet C; Demarquette H; Vermersch P; Morschhauser F; Herbaux C
Curr Res Transl Med; 2018 Sep; 66(3):87-89. PubMed ID: 30191811
[TBL] [Abstract][Full Text] [Related]
11. Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.
Hanlon A; Brander DM
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):346-356. PubMed ID: 33275709
[TBL] [Abstract][Full Text] [Related]
12. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
Fukuhara N; Kinoshita T; Yamamoto K; Nagai H; Izutsu K; Yamamoto G; Bhargava P; Rajakumaraswamy N; Humeniuk R; Mathias A; Xing G; Fukui M; Tobinai K
Jpn J Clin Oncol; 2020 Dec; 50(12):1395-1402. PubMed ID: 32856068
[TBL] [Abstract][Full Text] [Related]
13. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Gopal AK; Kahl BS; de Vos S; Wagner-Johnston ND; Schuster SJ; Jurczak WJ; Flinn IW; Flowers CR; Martin P; Viardot A; Blum KA; Goy AH; Davies AJ; Zinzani PL; Dreyling M; Johnson D; Miller LL; Holes L; Li D; Dansey RD; Godfrey WR; Salles GA
N Engl J Med; 2014 Mar; 370(11):1008-18. PubMed ID: 24450858
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma.
Izutsu K; Kato K; Kiyoi H; Yamamoto G; Shimada K; Akashi K
Int J Hematol; 2020 Oct; 112(4):504-509. PubMed ID: 32613313
[TBL] [Abstract][Full Text] [Related]
15. Idelalisib has activity in mantle cell lymphoma.
Cancer Discov; 2014 May; 4(5):OF8. PubMed ID: 24795031
[TBL] [Abstract][Full Text] [Related]
16. Idelalisib for treatment of B-cell malignancies.
Do B; Mace M; Rexwinkle A
Am J Health Syst Pharm; 2016 Apr; 73(8):547-55. PubMed ID: 26933132
[TBL] [Abstract][Full Text] [Related]
17. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Furman RR; Sharman JP; Coutre SE; Cheson BD; Pagel JM; Hillmen P; Barrientos JC; Zelenetz AD; Kipps TJ; Flinn I; Ghia P; Eradat H; Ervin T; Lamanna N; Coiffier B; Pettitt AR; Ma S; Stilgenbauer S; Cramer P; Aiello M; Johnson DM; Miller LL; Li D; Jahn TM; Dansey RD; Hallek M; O'Brien SM
N Engl J Med; 2014 Mar; 370(11):997-1007. PubMed ID: 24450857
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma.
Gopal AK; Fanale MA; Moskowitz CH; Shustov AR; Mitra S; Ye W; Younes A; Moskowitz AJ
Ann Oncol; 2017 May; 28(5):1057-1063. PubMed ID: 28327905
[TBL] [Abstract][Full Text] [Related]
19. Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study.
Marchesini G; Nadali G; Facchinelli D; Candoni A; Cattaneo C; Laurenti L; Fanci R; Farina F; Lessi F; Visentin A; Marchesi F; Prezioso L; Spolzino A; Tisi MC; Trastulli F; Picardi M; Verga L; Dargenio M; Busca A; Pagano L;
Br J Haematol; 2021 Apr; 193(2):316-324. PubMed ID: 33058237
[TBL] [Abstract][Full Text] [Related]
20. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.
Davies A
Expert Rev Hematol; 2015 Oct; 8(5):581-93. PubMed ID: 26343890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]